Preparation method of lesinurad related impurities

A technology for impurities and acidic substances, which is applied in the field of preparation of impurities related to Recinade, can solve the problems of difficult separation by column chromatography and difficult removal of impurities.
CN113979958APending Publication Date: 2022-01-28HAINAN XINOPEN SOURCE MEDICAL TECH CO LTD
4 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
HAINAN XINOPEN SOURCE MEDICAL TECH CO LTD
Publication Date
2022-01-28

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention provides a preparation method of lesinurad related impurities. Compared with the prior art, the preparation method has the advantages that intermediate related impurities and position isomer impurities of the lesinurad can be obtained, the synthesis method is simple, the obtained target product is high in purity, technological research and quality standard formulation of the lesinurad are facilitated, the research and development cost is effectively reduced, and the preparation method is of great significance to drug development.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the technical field of chemical synthesis, and in particular relates to a preparation method of a lecienard-related impurity. Background technique

[0002] Lesinurad was approved by the US Food and Drug Administration (FDA) on December 22, 2015. In addition, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the drug to be approved for marketing in the EU on December 18. The drug was previously developed by Ardea, which AstraZeneca acquired in 2012, giving it access to the product. The trade name of the drug in the United States is Zurampic.

[0003] Recinade is the world's first approved urate reabsorption transporter (URAT1) inhibitor, combined with a xanthine oxidase inhibitor to treat gout associated with hyperuricemia. Zurampic is a tablet for oral use, the strength is 200 mg. The recommended dose is 200 mg once daily in combination with allopurinol or febuxosta...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More